FIELD: biotechnology, medicine, oncology, pharmacy, molecular biology.
SUBSTANCE: invention relates to new nucleotide sequences in DNA and amino acid sequences in monoclonal antibodies (MAT) produced against lymphoblastoid cells and to peptides binding with MAT. Invention relates also to diagnosis analysis wherein above mentioned antibodies or peptides are used for detection of persons with high probability the presence of malignant diseases and, sometimes, for detection of person suffering with malignant disease. Except for, invention relates to pharmaceutical compositions comprising MAT or peptides and designated for using in treatment of different malignant diseases, and also to methods for treatment of malignant disease using MAT or peptides. The application of invention will allow carrying out the differential diagnosis of cancer.
EFFECT: improved method for diagnosis and treatment, valuable medicinal properties of antibody, nucleic acid and vector.
30 cl, 18 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2562874C1 |
| ANTIBODIES SPECIFIC TO HUMAN CD22, AND THEIR USES IN THERAPY AND DIAGNOSTICS | 2003 |
|
RU2342401C2 |
| ANTIBODIES | 2005 |
|
RU2482131C2 |
| ANTIBODY AGAINST PD-L1 | 2017 |
|
RU2744862C2 |
| MONOCLONAL ANTIBODIES AND METHODS OF USING THEM | 2017 |
|
RU2694412C2 |
| ANTIBODIES SPECIFIC TO CLAUDIN 6 (CLDN6) | 2010 |
|
RU2675997C2 |
| ILT17 ANTIBODY | 2012 |
|
RU2599450C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
| HUMANIZED ANTIBODY TO CD52 | 2012 |
|
RU2605307C2 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2013 |
|
RU2551235C2 |
